<DOC>
	<DOC>NCT00167908</DOC>
	<brief_summary>The purpose of this study is to determine whether Amifostine provides additional protection of salivary gland function over that achieved with IMRT alone.</brief_summary>
	<brief_title>Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Pathologically confirmed squamous cell cancer of the head and neck Eligible sites: oral cavity, oropharynx, hypopharynx, larynx. Patients requiring postoperative IMRT. KPS &gt; 70%. Patient has signed specific protocol consent prior to registration. Calcium test within normal limits. No previous malignancy except for nonmelanoma skin cancer or cancer not of head and neck and controlled for at least 5 years. Labs completed with 30 days of registration (CBC &amp; platelet, Ca++, Alk phos, SGOT, Bili, albumin) CXR and CT simulation. Liver CT if alk phos, SGOT, or bili elevated. Bone scan if elevated alk phos Metastatic disease. Patient using Salagen or concurrent chemotherapy. Previous XRT for head and neck tumors. Active untreated infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>